| Market Cap | 51.14M | P/E | - | EPS this Y | 61.40% | Ern Qtrly Grth | - |
| Income | -7.47M | Forward P/E | - | EPS next Y | 45.50% | 50D Avg Chg | 12.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 11.00% |
| Dividend | N/A | Price/Book | 3.29 | EPS next 5Y | - | 52W High Chg | -38.00% |
| Recommedations | 2.00 | Quick Ratio | 1.96 | Shares Outstanding | 708.61K | 52W Low Chg | 112.00% |
| Insider Own | 9.74% | ROA | -36.47% | Shares Float | 600.70K | Beta | - |
| Inst Own | 2.69% | ROE | -63.89% | Shares Shorted/Prior | 2.72K/1.51K | Price | 1.31 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 94,872 | Target Price | 2.60 |
| Oper. Margin | - | Earnings Date | Nov 12 | Volume | 2,061,134 | Change | -0.76% |
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.